PDE-5 inhibitors: patients’ preferences


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

To date, multidisciplinary approach is commonly used to treat erectile dysfunction (ED), and the first line of ED pharmacotherapy, despite its multiple causes, is phosphodiesterase inhibitors of type 5 (PDE-5). They are considered an effective and well tolerated treatment option [1-4]. Concurrently, sildenafil has the largest evidence base for efficacy and safety [5]. The satisfaction of patients with ED therapy is a complex and personal matter, and there are no clearly established and reliable criteria for showing preferences when choosing a PDE-5. Adherence of patients to the PDE-5 therapy is determined not only by the erectile response and side effects, but also by how well the treatment meets the needs and expectations of patients and how it affects the relationship between the partners. This review examines the tolerability and efficacy of the various types of PDE-5 available for treating ED, with a special emphasis on the patient's preferences, and in particular on the new sildenafil orodispersible films. As an alternative route of drug administration, films quickly dissolve in the mouth [6] and have several advantages, improve sexual health and the sense of psychological well-being of patients and their partners.

Full Text

Restricted Access

About the authors

E. A Efremov

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Dr.Med.Sci. Head of the Department of Andrology and Human Reproduction

E. V Kasatonova

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Email: kasatonova@yandex.ru
Researcher at the Department of Andrology and Human Reproduction

Ya. I Mel’nik

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Researcher at the Department of Andrology and Human Reproduction

A. A Nikushina

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of NMRRC of Minzdrav of Russia

Researcher at the Research and Methodology Department of Andrology and Human Reproduction

References

  1. Bella A.J., Lee J.C., Carrier S., Bénard F., Brock G.B. 2015 CUA Practice guidelines for erectile dysfunction. Canadian Urological Association Journal. 2015;9(1-2):23-29. doi: 10.5489/cuaj.2699.
  2. Nehra A., Jackson G., Miner M. et al. The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. Mayo Clinic Proceedings. 2012;87(8):766-778. doi: 10.1016/j.mayocp.2012.06.015.
  3. Ryu J.K., Cho K.S., Kim S.J. et al. Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction. The World Journal of Men’s Health. 2013;31(2):83-102. Doi:10.5534/ wjmh.2013.31.2.83.
  4. Yafi F.A., Jenkins L., Albersen M. et al. Erectile dysfunction. Nature reviews Disease primers. 2016;2:16003. doi: 10.1038/nrdp.2016.3.
  5. С. силденафилом проведено более 800 исследований http://www. ncbi.nlm.nih.gov/ доступ от 20.06.2017
  6. Исключительно процесс растворения пленки, помещенной на язык. Пленка растворяется на языке приблизительно в течение 60 секунд. Data on file («A Clinical study in healthy male volunteers to evaluate buccal absorption of Please Orally Soluble Film 50 mg (Sildenafil)», Protocol Number CTC-CDF-003 Ver.1.5).
  7. Пушкарь Д.Ю., Камалов А.А., Аль-Шукри С.Х., Еркович А.А., Коган М.И., Павлов В.Н., Журавлев В.Н., Берников А.Н. Эпидемиологическое исследование распространенности эректильной дисфункции в Российской Федерации. Урология. 2012;6:5-9
  8. Sharlip I.D. Opinion: No. Ten reasons that there will be no new pharmacologic therapies for erectile dysfunctionin the foreseeable future. International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology. 2015;41(5):832-834. Doi:10.1590/ S1677-5538.IBJU.2015.05.03.
  9. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J. Impot Res. 1996;8(2):47-52.
  10. Yuan J., Zhang R., Yang Z., Lee J., Liu Y., Tian J., Qin X., Ren Z., Ding H., Chen Q., Mao C., Tang J. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63(5):902-912. doi: 10.1016/j.eururo.2013.01.012.
  11. Chen L., Staubli S.E., Schneider M.P., Kessels A.G., Ivic S., Bachmann L.M., Kessler T.M. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-offnetwork meta-analysis. Eur Urol. 2015;68(4):674- 80. doi: 10.1016/j.eururo.2015.03.031.
  12. Nehra A., Jackson G., Miner M. et al. The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. Mayo Clinic Proceedings. 2012;87(8):766-778.
  13. Porst H. Standard practice in sexual medicine. 1st ed. Blackwell Publishing; 2006. 2006. Oral pharmacotherapy of erectile dysfunction; pp. 83-86.
  14. Leoni L.A., Leite G.S., Wichi R.B., Rodrigues B. Sildenafil: two decades of benefits or risks? Aging Male. 2013; 16(3):85-91. doi: 10.3109/13685538.2013.801952.
  15. McMahon C.M., Kozlowski R.K., Kaufman A.K. et al. Potential predictors for treatment preference in men with erectile dysfunction taking sildenafil and tadalafil in an open-label switch trial [abstract]. J. Sex Med. 2004;(1 Suppl. 1):40.
  16. Eardley I., Mirone V., Montorsi F. et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int. 2005;96:1323-1332.
  17. Kell P., Hvidsten K., Morant S. et al. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. BJU Int. 2007;99:860-863. doi: 10.1111/j.1464-410X.2006.06668.x
  18. Hedelin H., Stroberg P. Treatments for erectile dysfunction based on patient-reported outcomes. Drugs.2005;65:2245-2251.
  19. Пушкарь Д.Ю., Раснер П.И. Эректильная дисфункция. Библиотека пациента. Урология. РМЖ. 2013;18:6
  20. Stroberg P., Hedelin H., Ljunggren C. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction - a realistic and feasible option in everyday clinical practice - outcomes of a simple treatment regime. Eur Urol. 2006;49:900-907. doi: 10.1016/j.eururo.2006.02.032.
  21. Corona G., Rastrelli G., Burri A., Jannini E.A., Maggi M. The safety and efficacy ofAvanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. Expert Opin Drug Saf. 2016; 15(2):237-247. doi: 10.1517/14740338.2016.1130126. doi: 10.1517/14740338.2016.1130126.
  22. Souverein P.C., Egberts A.C., Meuleman E.J. et al. Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. Int J. Impot Res. 2002;14:259-265. doi: 10.1038/sj.ijir.3900883.
  23. Sato Y., Tanda H., Kato S. et al. How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. Int J. Urol. 2007;14:339-342. doi: 10.1111/j.1442-2042.2007.01608.x.
  24. Sommer F., Engelmann U. Future options for combination therapy in the management of erectile dysfunction in older men. Drugs Aging. 2004;21:555-564.
  25. McCullough A. R., Barada J.H., Fawzy A. et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60(2 Suppl. 2):28-38.
  26. McMahon C.G. High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Int J. Impot Res. 2002;14(6):533-538. Doi: 10.1038/ sj.ijir.3900936.
  27. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J. Sex Med. 2004;1:292-300. doi: 10.1111/j.1743-6109.04042.x.
  28. Porst H. Salvagetherapie mit taglicher dosierung von sildenafil bei nonrespondern auf on-demand therapie mit 100 mg sildenafil. Urologe A. 2003;42(10):1330-1336.
  29. Deyoung L., Chung E., Kovac J.R., Romano W., Brock G.B. Daily use of sildenafil improves endothelial function in men with type 2 diabetes. J. Androl. 2012;33(2):176-80. doi: 10.2164/jandrol.111.013367.
  30. Дутов В.В. Выбор ингибиторов фосфодиэстеразы 5-го типа для лечения эректильной дисфункции в урологической практике. РМЖ. 2014;17:1280.
  31. Gupta B.P., Murad M.H., Clifton M.M., Prokop L., Nehra A., Kopecky S.L. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011;171(20):1797-803. doi: 10.1001/archinternmed.2011.440.
  32. Zitzmann M., Mattern A., Hanisch J., Gooren L., Jones H., Maggi M. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J. Sex Med. 2013;10(2):579-88. doi: 10.1111/j.1743-6109.2012.02853.x.
  33. Huri H.Z., Ling C.F., Razack A.H. Drug-related problems in patients with erectile dysfunctions and multiple comorbidities. Ther Clin Risk Manag. 2017;13:407-419. doi: 10.2147/TCRM.S118010.
  34. Hatzimouratidis K. Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. Clinical Interventions in Aging. 2006;1(4):403-414.
  35. Gacci M., Corona G., Salvi M., Vignozzi L., McVary K.T., Kaplan S.A., Roehrborn C.G., Serni S., Mirone V., Carini M., Maggi M. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033.
  36. Камалов А.А. и соавт. Комбинированная терапия больных с симптомами нижних мочевых путей и эректильной дисфункцией. Естественные и технические науки. 2013;1:99-107
  37. Kostis J.B., Jackson G., Rosen R. et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J. Cardiol. 2005;96:313-21. doi: 10.1016/j.amjcard.2005.03.065.
  38. Mulhall J.P., Guhring P., Parker M., Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J. Sex Med 2006;3:662-67. Doi: 10.1111/j. 1743- 6109.2006.00259.x
  39. McVary K.T., Monnig W., Camps J.L., Young J.M., Tseng L.J., Van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J. Urol 2007;177:1071-77. doi: 10.1016/j.urology.2008.04.020.
  40. Klotz T., Mathers M., Klotz R., Sommer F. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra) Int J. Impot Res. 2005;17:2-4. doi: 10.1038/sj.ijir.3901252.
  41. Jiann B.P., Yu C.C., Su C.C., Tsai J.Y. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J. Impot Res. 2006;18:146-149. doi: 10.1038/sj.ijir.3901379.
  42. Son H., Park K., Kim S.W., Paick J.S. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J. Androl. 2004;6:117-120.
  43. Giannitsas K., Konstantinopoulos A., Patsialas C., Perimenis P. Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. Patient preference and adherence. 2008;2: 149-155.
  44. Althof S.E. When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J. Impot Res. 2002;14(Suppl. 1):S99-S104. doi: 10.1038/sj.ijir.3900799.
  45. Kim S.-C., Lee Y.-S., Seo K.-K., Jung G.-W., Kim T.-H. Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients. International Journal of Impotence Research. 2014;26(3):87-93. Doi:10.1038/ ijir.2013.41.
  46. Braun M. et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey'. Int J. Impot Res. 2000;12:305-311.
  47. Kim S.C. Sexual attitude and perception on sexual relationship among long-term users of sildenafil. J. Sex Med. 2008;5:1088-1096. doi: 10.1111/j.1743-6109.2008.00816.x.
  48. Кульчавеня Е.В., Бреусов А.А. Роль силденафила в жизни мужчины и женщины. РМЖ. 2016;23:1542-1545
  49. Dadey E. Bioequivalence of 2 Formulations of Sildenafil Oral Soluble Film 100 mg and Sildenafil Citrate (Viagra) 100 mg Oral Tablets in Healthy Male Volunteers. Am J. Ther. 2015 Jul 4. Doi: 10.1097/ MJT.0000000000000302.
  50. Kathpalia H., Gupte A. An introduction to fast dissolving oral thin film drug delivery systems: a review. Curr Drug Deliv. 2013;10(6):667-84.
  51. Shimoda H., Taniguchi K., Nishimura M., Matsuura K., Tsukioka T., Yamashita H., Inagaki N., Hirano K., Yamamoto M., Kinosada Y., Itoh Y. Preparation of a fast dissolving oral thin film containing dexamethasone: a possible application to antiemesis during cancer chemotherapy. Eur J. Pharm Biopharm. 2009;73(3):361-65. doi: 10.1016/j.ejpb.2009.08.010.
  52. Yellanki S., Jagtap S., Masareddy R. Dissofilm: a novel approach for delivery of phenobarbital; design and characterization. J. Young Pharm. 2011;3(3):181-188. doi: 10.4103/0975-1483.83756.
  53. Lee Y., Thapa P., Jeong S.H., Woo M.H., Choi D.H. Formulation Optimization and in Vitro Characterization of Orally Disintegrating Films Using a Factorial Design and Mathematical Modeling for Drug Release. Chem Pharm Bull (Tokyo). 2017;65(2):166-177. doi: 10.1248/cpb.c16-00757.
  54. Howden C.W. Management of acid-related disorders in patients with dysphagia. Am J. Med. 2004;117(Suppl 5A):44S-48S.
  55. Roh H., Son H., Lee D., Yeon K.J., Kim H.S., Kim H., Park K. Pharmacokinetic comparison of an orally disintegrating film formulation with a film-coated tablet formulation of sildenafil in healthy Korean subjects: a randomized, open-label, single-dose, 2-period crossover study. Clin Ther. 2013;35(3):205-214. doi: 10.1016/j.clinthera.2013.02.006.
  56. Zaid A.N., Ramahi R.A., Bustami R., Mousa A. Formulation and bioequivalence of two sildenafil 50 mg film-coated tablets after a single oral administration. Int J. Clin Pharmacol Ther. 2015;53(8):697-704. doi: 10.5414/CP202298.
  57. Kim E.Y., Lee S.Y., Jeon J.Y., Im Y.J., Kim Y., Kim H.I., Shin K.S., Park S.J., Seo Y.H., Lee J.Y., Park J.K., Chae S.W., Kim M.G. Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. Int J. Clin Pharmacol Ther. 2014;52(6):437-45. Doi: 10.5414/ CP201995.
  58. Radicioni M., Castiglioni C., Giori A., Cupone I., Frangione V., Rovati S. Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers. Drug Des Devel Ther. 2017;11:1183-1192. doi: 10.2147/DDDT.S124034.
  59. Инструкция по медицинскому применению лекарственного препарата Динамико Форвард.
  60. Raheem A.A., Kell P. Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil. Patient preference and adherence. 2009;3:99-104.
  61. Smith W.B., 2nd, McCaslin I.R., Gokce A., Mandava S.H., Trost L., Hellstrom W.J. PDE5 inhibitors: considerations for preference and longterm adherence. Int J. Clin Pract. 2013;67(8):768-780. Doi: 10.1111/ ijcp.12074.
  62. Doggrell S. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Int J. Impot Res. 2007;19(3):281- 295. doi: 10.1038/sj.ijir.3901525.
  63. Hackett G.I. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone. 2005;7(1):57-65.
  64. Mirone V., Fusco F., Rossi A., Sicuteri R., Montorsi F. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. BJU Int. 2009;103(9):1212-1217. doi: 10.1111/j.1464-410X.2008.08267.x.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies